Age: 17.0
Sex: M
Vaccine: COVID19
Symptoms: Adenovirus test, Blood creatine phosphokinase, Blood creatine phosphokinase MB, Blood creatine phosphokinase MB increased, Blood creatine phosphokinase increased
Clinical narrative: elevated Troponins, CK, CK MB, EKG showed ST segment elevation, trivial effusion, normal coronaries, and low to normal function; elevated Troponins, CK, CK MB, EKG showed ST segment elevation, trivial effusion, normal coronaries, and low to normal function; elevated Troponins, CK, CK MB, EKG showed ST segment elevation, trivial effusion, normal coronaries, and low to normal function; elevated Troponins, CK, CK MB, EKG showed ST segment elevation, trivial effusion, normal coronaries, and low to normal function; elevated Troponins, CK, CK MB, EKG showed ST segment elevation, trivial effusion, normal coronaries, and low to normal function; Myocardial Injury; sudden chest pain that  woke him up and got worse; This is a spontaneous report from a contactable physician. A 17-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration on 21May2021 (Lot Number: EW0618) (at the age of 17 years old) as 2nd dose, single dose for COVID-19 immunisation. Medical history allergies, compromised immune status, respiratory illness, genetic/chromosomal abnormalities, endocrine abnormalities (including diabetes) and obesity from an unknown date. The patient's concomitant medications were not reported. No reported family medical history relevant to adverse events (AE), no reported cardiac arrhythmias, myocardial infarction (MI) under 50, no early deaths, nor any pertinent history. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EW0619) on Apr2021 for COVID-19 immunization. The patient experienced myocardial injury on 23May2021, 2 days after he received his second Covid vaccine with possible association. It was stated that the patient came in to the emergency room (ER) about 28 hours after his second vaccine with sudden chest pain that woke him up and got worse. Further stated that the patient was seen at an outside emergency department (ED) and had elevated troponins, creatine kinase (CK), creatine kinase-MB (CK MB), electrocardiogram (EKG) showed ST segment elevation, Echo showed trivial effusion, normal coronaries, and low to normal function. It was reported that he was admitted for monitoring due to potentially decompensating. Stated that he was consulted because of the association with the vaccine, and viral testing was done; the patient was tested for enterovirus, adenovirus, cytomegalovirus (CMV), epstein-barr virus (EBV), and parvovirus, all were negative. Treatment received was intravenous immune globulin (IVIG), pain medication and general support. States that the patient did receive IVIG while he was there, a one time dose, because the cardiologist was concerned with the way his troponins were trending, no decompensation. Further stated that the patient did not receive any pressors at any point and that the patient was still in the hospital but he was being transferred to the floor and they were trending labs, but he was not on any pressors or anything and he seemed like he has been doing well. There were no additional vaccines administered on same date of the Pfizer suspect. Chest pain and myocardial injury required a visit to Emergency Room on 23May2021. No prior vaccinations (within 4 weeks). No or unknown AE following prior vaccinations. As per the reporter all events seriousness criteria reported as medically significant, hospitalization. The patient was hospitalized from 24May2021 and ongoing at the time of the report (also reported as 2 days and counting). The outcome of all the events was recovering.; Sender's Comments: Based solely on chronological connection to the vaccine causality between reported events and BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) cannot be completely excluded. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.